KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Xenon Pharmaceuticals (XENE) over the last 5 years, with Q3 2025 value amounting to $45.2 million.

  • Xenon Pharmaceuticals' Total Non-Current Liabilities changed N/A to $45.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.2 million, marking a year-over-year change of. This contributed to the annual value of $43.2 million for FY2024, which is N/A changed from last year.
  • Per Xenon Pharmaceuticals' latest filing, its Total Non-Current Liabilities stood at $45.2 million for Q3 2025.
  • Xenon Pharmaceuticals' 5-year Total Non-Current Liabilities high stood at $45.2 million for Q3 2025, and its period low was $43.2 million during Q4 2024.